Video navigation menu

• Clinical benefit of conventional inhibitors of the renin-angiotensin system (RAS). 0:01
• The search for better ways to inhibit RAS. 0:32
• Effects of simultaneous inhibition of RAS and neprilysin by sacubitril-valsartan (LCZ696). 1:18
• Implications of the PARADIGM-HF trial for clinical practice. 2:25